|
2.6 ETIOLOGIE - ENVIRONNEMENT
|
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
|
|
|
|
Merck Makes a Big Blood Cancer Bet With $2.7B Deal for ArQule [Xconomy]
|
|
|
|
|
|
Lead ArQule drug candidate ARQ 531 is a small molecule currently in Phase 2 dose expansion study in B-cell malignancies, or blood cancers, that have not responded to other treatments. The drug targets Bruton’s tyrosine kinase (BTK), a protein that plays a key role in the expansion of chronic lymphocytic leukemia (CLL), the most common form of leukemia.
|
|
|
|
|
|
|
|
|
|
|
5.8.3 ASH - DIVERS
|
|
|
|
|
5.8.4 ASH - CAR-T
|
|
|
|
|
|
5.8.5 ASH - MYÉLOME MULTIPLE
|
|
|
|
|
|
|
|
|
|
5.8.6 ASH - LEUCÉMIES
|
|
|
|
|
Leukemia Combo Toxic for Old, Frail Patients [SWOG]
|
|
|
|
|
|
About 32 percent of older, sicker patients enrolled on a leukemia clinical trial experienced serious side effects from a treatment that combined a chemotherapy and an immunotherapy drug, leading investigators to pause the trial and the U.S. Food and Drug Administration to eventually pull the combination from the current study.
|
|
|
|
|
|
|
5.8.7 ASH - LYMPHOMES
|
|
|
|
|
|
|
6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES
|
|
|
Spinning a negative acupuncture study: Same as it ever was [Science-Based Medicine]
|
|
|
|
|
|
Investigators at M.D. Anderson Cancer Center reported the results of a trial of acupuncture for xerostomia (dry mouth) secondary to radiation therapy for head and neck cancers. It was a negative trial, but investigators still tried to spin it as positive, but with a twist. There was a large difference between results found at M.D. Anderson and the second site in China. What could be going on?
|
|
|
|
|
|